Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale
Advertisement
Articles by Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale
Takeaways on Treatment of Early-Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Risk of Pneumonitis Post-Chemoradiation in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Considering PD-L1 and EGFR Status With I/O in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
PACIFIC Trial in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Future of Neoadjuvant I/O in ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Neoadjuvant I/O for ES NSCLC: Key Trials from ESMO 2020
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Key Trials in Neoadjuvant I/O for ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Role of Neoadjuvant I/O in ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Patient Selection: Adjuvant Therapy and Testing for ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Phase 3 ADAURA Study: EGFR-Mutated NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Role of Postoperative Radiotherapy in Early Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Neoadjuvant Chemotherapy in Early-Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Treatment of Early-Stage NSCLC: Current Standard of Care
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Advertisement
Latest Updated Articles
Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431Published: October 31st 2023 | Updated:
Neoadjuvant I/O for ES NSCLC: Key Trials from ESMO 2020Published: October 26th 2020 | Updated:
Takeaways on Treatment of Early-Stage NSCLCPublished: October 26th 2020 | Updated:
Phase 3 ADAURA Study: EGFR-Mutated NSCLCPublished: October 26th 2020 | Updated:
Neoadjuvant Chemotherapy in Early-Stage NSCLCPublished: October 26th 2020 | Updated:
PACIFIC Trial in Stage 3 NSCLCPublished: October 26th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5